The role of TRAIL in immune control of cytomegalovirus
TRAIL在巨细胞病毒免疫控制中的作用
基本信息
- 批准号:8984862
- 负责人:
- 金额:$ 44.25万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2013
- 资助国家:美国
- 起止时间:2013-01-10 至 2017-12-31
- 项目状态:已结题
- 来源:
- 关键词:Acute DiseaseAntibodiesAntiviral AgentsApoptosisAttenuatedBlocking AntibodiesCD4 Positive T LymphocytesCellsCessation of lifeChronicCytomegalovirusCytomegalovirus InfectionsDataDevelopmentDiseaseEpitopesEquilibriumFamilyGenesHealthHerpesviridaeHerpesviridae InfectionsHomeostasisHost DefenseHumanImmuneImmune System DiseasesImmune responseImmunityInfectionInterleukin-10LigandsMediatingMurid herpesvirus 1MusMutant Strains MiceNatural Killer CellsOrganPathway interactionsPersonsPhasePopulationProteinsReceptor SignalingRegulationRegulatory T-LymphocyteRoleSalivary GlandsSignal PathwaySignal TransductionSystemT cell responseT-LymphocyteTNF geneTNF-related apoptosis-inducing ligandTestingViralViral ProteinsVirusVirus LatencyWild Type MouseWorkattenuationcytokinefightingheuristicsin vivokiller T celllatent persistent infectionmucosal sitemutantreceptorviral fitness
项目摘要
DESCRIPTION (provided by applicant): Tumor necrosis factor (TNF)-related cytokines are critical for antiviral defense, and are important for maintaining immune homeostasis during chronic infection. Cytomegalovirus (CMV, a ¿-herpesvirus) infection is normally subclinical despite inducing a robust immune response and establishing lifelong persistence/latency, causing acute disease only if host defenses are immature or compromised. CMV accomplishes this by employing many tactics that modulate host immunity, several which target the TNF-family. We have recently identified specific proteins in both human and mouse CMV (MCMV) that inhibit the TNF-related apoptosis inducing ligand (TRAIL) death receptors (UL141 and m166, respectively). A MCMV mutant lacking m166 (MCMV¿m166) shows reduced early replication, suggesting TRAIL-mediated innate defenses are normally neutralized by m166 in vivo. In stark contrast, persistent replication of MCMV¿m166 is enhanced, indicating that viral inhibition of TRAIL DR signaling may promote adaptive immune control of chronic infection. This hypothesis is supported by our results showing that TRAIL-R2-/- mice control MCMV persistence better than wild- type mice. Our identification of specific CMV proteins that inhibit TRAIL DR has revealed new roles for this TNF-related signaling pathway in regulating the early and later phases of a herpesvirus infection. In this proposal we will determine the mechanism(s) by which TRAIL DR signaling, and m166 inhibition of this pathway, function to regulate innate and adaptive immune control of MCMV infection. The fact that both mouse and human CMV encode specific proteins that restrict expression of the TRAIL DR strongly suggests this TNF-related cytokine system regulates CMV infection in humans, and consequently these studies will provide heuristic value.
描述(由适用提供):肿瘤坏死因子(TNF)相关的细胞因子对于抗病毒防御至关重要,对于在慢性感染过程中维持免疫稳态至关重要。巨细胞病毒(CMV,A€-HERPESVIRUS)的感染通常是亚临床的任务,诱导强大的免疫响应并建立终身持久/潜伏期,仅当宿主防御不成熟或不成熟时,才会导致急性疾病。 CMV A MCMV突变体缺乏M166(MCMV¿M166)显示早期复制减少,这表明TRAIL介导的先天防御通常被M166在Vivo中中和。与之形成鲜明对比的是,MCMV¿M166的持续复制得到了增强,这表明对TRAIL DR信号传导的病毒抑制可能促进对慢性感染的适应性免疫控制。我们的结果支持了这一假设,表明TRAIL-R2 - / - 小鼠控制MCMV持久性比野生型小鼠更好。我们对抑制TRAIL DR的特定CMV蛋白的鉴定已经揭示了这种与TNF相关的信号通路在调节疱疹病毒感染的早期和后期中的新作用。在此提案中,我们将确定TRAIL DR信号传导的机制以及对该途径的M166抑制,以调节MCMV感染的先天和适应性免疫控制。小鼠和人CMV编码限制TRAIL DR表达的特定蛋白质的事实强烈表明,这种与TNF相关的细胞因子系统调节了人类中CMV的感染,因此这些研究将提供启发式价值。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
CHRISTOPHER A BENEDICT其他文献
CHRISTOPHER A BENEDICT的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('CHRISTOPHER A BENEDICT', 18)}}的其他基金
Necroptosis and adaptive immunity to virus infection
坏死性凋亡和对病毒感染的适应性免疫
- 批准号:
9334693 - 财政年份:2016
- 资助金额:
$ 44.25万 - 项目类别:
The role of TRAIL in immune control of cytomegalovirus
TRAIL在巨细胞病毒免疫控制中的作用
- 批准号:
8502935 - 财政年份:2013
- 资助金额:
$ 44.25万 - 项目类别:
The role of TRAIL in immune control of cytomegalovirus
TRAIL在巨细胞病毒免疫控制中的作用
- 批准号:
10624385 - 财政年份:2013
- 资助金额:
$ 44.25万 - 项目类别:
The role of TRAIL in immune control of cytomegalovirus
TRAIL在巨细胞病毒免疫控制中的作用
- 批准号:
8604371 - 财政年份:2013
- 资助金额:
$ 44.25万 - 项目类别:
The role of TRAIL in immune control of cytomegalovirus
TRAIL在巨细胞病毒免疫控制中的作用
- 批准号:
10180877 - 财政年份:2013
- 资助金额:
$ 44.25万 - 项目类别:
The role of TRAIL in immune control of cytomegalovirus
TRAIL在巨细胞病毒免疫控制中的作用
- 批准号:
8786869 - 财政年份:2013
- 资助金额:
$ 44.25万 - 项目类别:
The role of TRAIL in immune control of cytomegalovirus
TRAIL在巨细胞病毒免疫控制中的作用
- 批准号:
10410513 - 财政年份:2013
- 资助金额:
$ 44.25万 - 项目类别:
相似国自然基金
人源化小鼠筛选猴痘抗体及机制研究
- 批准号:82373778
- 批准年份:2023
- 资助金额:48 万元
- 项目类别:面上项目
抗HTNV抗体mRNA修饰MSC在肾综合征出血热治疗中的作用研究
- 批准号:82302487
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
人和小鼠中新冠病毒RBD的免疫原性表位及其互作抗体的表征和结构组学规律的比较研究
- 批准号:32371262
- 批准年份:2023
- 资助金额:50 万元
- 项目类别:面上项目
靶向肿瘤内T细胞的双特异性抗体治疗策略研究
- 批准号:82371845
- 批准年份:2023
- 资助金额:49 万元
- 项目类别:面上项目
靶向DLL3和γδ T细胞的双特异抗体对小细胞肺癌的免疫治疗活性研究
- 批准号:32300783
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
相似海外基金
Development of antibody drug conjugates as pan-filo antivirals
开发作为泛型抗病毒药物的抗体药物偶联物
- 批准号:
10759731 - 财政年份:2023
- 资助金额:
$ 44.25万 - 项目类别:
Development of an Oral Pan-Coronavirus Drug Cocktail
口服泛冠状病毒药物混合物的开发
- 批准号:
10714472 - 财政年份:2023
- 资助金额:
$ 44.25万 - 项目类别:
Host Defense Small Molecule Development for COVID-19 Treatment by Targeting Lysosome
通过靶向溶酶体治疗 COVID-19 的宿主防御小分子开发
- 批准号:
10735492 - 财政年份:2023
- 资助金额:
$ 44.25万 - 项目类别:
Broadly neutralizing SARS-CoV-2 peptidic knobs
广泛中和 SARS-CoV-2 肽旋钮
- 批准号:
10735902 - 财政年份:2023
- 资助金额:
$ 44.25万 - 项目类别:
Broad spectrum inhibitors of paramyxovirus envelope proteins
副粘病毒包膜蛋白的广谱抑制剂
- 批准号:
10634368 - 财政年份:2023
- 资助金额:
$ 44.25万 - 项目类别: